2022 World Conference on Lung Cancer (ePosters)-EP08.01-050. Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)

EP08.01-050. Survival Outcome of Metastatic Pulmonary Sarcomatoid Carcinoma Treated with Immunotherapy: An Analysis of National Cancer Database (NCDB)

Back to course

Pdf Summary

Pulmonary sarcomatoid carcinoma (PSC) is a rare type of non-small cell lung cancer (NSCLC) that is difficult to treat and has a poor prognosis. However, the effectiveness of immunotherapy in treating PSC compared to other forms of NSCLC is still uncertain. <br /><br />In this study, the National Cancer Database (NCDB) was analyzed to assess the survival outcomes of patients with stage IV PSC or squamous cell NSCLC who received either immunotherapy or chemotherapy as their first-line treatment. The researchers adjusted for various factors, including age, gender, race, academic center, insurance status, and comorbidity.<br /><br />The results showed that when treated with modern immunotherapy alone, PSC was not associated with worse survival compared to squamous NSCLC, similar to the era of chemotherapy. The overall survival (OS) for patients with PSC treated with immunotherapy alone was 8.9 months, while for squamous NSCLC, it was 9.1 months. The hazard ratio (HR) comparing the two groups was 0.92, indicating no significant difference in survival.<br /><br />On the other hand, when treated with chemotherapy alone, patients with PSC had a significantly worse survival compared to squamous NSCLC. The OS for PSC patients treated with chemotherapy alone was 3.8 months, while for squamous NSCLC, it was 7.6 months. The HR comparing the two groups was 1.60, indicating a higher risk of death for PSC patients.<br /><br />One limitation of the study was that the role of PD-L1, a biomarker associated with response to immunotherapy, could not be assessed because the data on PD-L1 status was not available in the NCDB.<br /><br />In conclusion, the study suggests that PSC may not have a worse survival outcome than squamous NSCLC when treated with immunotherapy alone. However, further research is needed to understand the role of PD-L1 in predicting the response to immunotherapy in PSC patients.

Asset Subtitle

Lei Deng

Meta Tag

Speaker Lei Deng

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Pulmonary sarcomatoid carcinoma

non-small cell lung cancer

NSCLC

immunotherapy

chemotherapy

survival outcomes

National Cancer Database

stage IV

squamous cell NSCLC

hazard ratio